Supplementary Figure S6 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma

Ahmad A. Tarhini; Alyssa Obermayer; Sandra J. Lee; William A. LaFramboise; F. Stephen Hodi; Arivarasan Karunamurthy; Islam Eljilany; Dung‐Tsa Chen; Patrick Hwu; Issam El Naqa; Howard Streicher; Vernon K. Sondak; Walter J. Storkus; Lisa H. Butterfield; Timothy I. Shaw; John M. Kirkwood

doi:10.1158/1078-0432.29760695

August 1, 2025

Supplementary Figure S6 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma

View at Publisher

Ask AI

Bookmark

Share

Key Points

MAIN FINDING: The study presents a method to enhance the predictive power of immunotherapeutic treatments for melanoma.
KEY EVIDENCE: Cross-validation analysis demonstrates the effectiveness of combined circulating and tumoral biomarkers.
APPROACH: Researchers used immune signatures to analyze biomarkers in high-risk melanoma patients.
SIGNIFICANCE: Improved predictions could lead to better immunotherapy outcomes, benefiting melanoma treatment strategies.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Cross-validation shows immune signature maximizes predictive power of immunotherapeutic benefits in melanoma patients, implying enhanced treatment effectiveness.

Abstract

Supplementary Figure S6. Cross-validation curve.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tarhini et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d01d4 https://doi.org/10.1158/1078-0432.29760695

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure S6 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S6 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers